VIRACTA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.612 USD | -96.71% |
|
0.00% | 0.00% |
| 06-12 | XOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher | MT |
| 05-30 | Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 52.85B | - | |||||
| 38.87B | ||||||
| 38.24B | ||||||
| 26.79B | ||||||
| 26.16B |
